Lead story
GSK Secures Cancer Breakthrough with $10.6 Billion Nuvalent Acquisition
GSK Plc is set to acquire Nuvalent for $10.6 billion, paying $124 per share. The move aims to boost GSK's oncology treatments. | Business News
